Precision BioSciences

Precision BioSciences

Biotechnology
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

$206.7M

Market Cap • 11/20/2026

2006

(20 years)

Founded

2019

(7 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4

P/S

4,6

P/EBITDA

1,6

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,9

EPS

0,2

Market Cap

Market Cap

206,7M

EV

152,6M

EV/Revenue

3,4

EV/EBITDA

1,2

EV/EBIT

1,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-43,2%

Total Yield

-43,2%

Payout

0%

Retained Earnings

-586,9M

Profitability

Gross Margin

100%

EBITDA Margin

282,8%

EBIT Margin

280,3%

Net Margin

273%

D&A/EBITDA

0%

R&D/Revenue

-117%

Capex/Revenue

0,1%

Capex/D&A

3,3%

Capex/OCF

-0,1%

SBC/OCF

—

% PPE

4,6%

% Goodwill

0%

ROE

359,5%

ROIC

320,7%

Growth

CAGR Revenue 5Y

-17,5%

CAGR Op. Income 5Y

-14%

CAGR Net Income 5Y

-14,5%

CAGR EPS 5Y

-44,3%

CAGR OCF 5Y

142%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

10,5

Quick Ratio

9,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium